A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Trial details
- Registry ID
- NCT05709444
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Angiotensin II receptor blockers (ARBs); Angiotensin-converting enzyme (ACE) inhibitors
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseNCT05709444 | PTN | Phase 2 | Completed | 2024-04-26Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |